EA200802012A1 - Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением - Google Patents

Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением

Info

Publication number
EA200802012A1
EA200802012A1 EA200802012A EA200802012A EA200802012A1 EA 200802012 A1 EA200802012 A1 EA 200802012A1 EA 200802012 A EA200802012 A EA 200802012A EA 200802012 A EA200802012 A EA 200802012A EA 200802012 A1 EA200802012 A1 EA 200802012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solution
under pressure
pharmaceutical preparations
active drug
drug substances
Prior art date
Application number
EA200802012A
Other languages
English (en)
Other versions
EA016262B1 (ru
Inventor
Дэвид Эндрю Льюис
Брайан Джон Микин
Гаэтано Брамбилла
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200802012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA200802012A1 publication Critical patent/EA200802012A1/ru
Publication of EA016262B1 publication Critical patent/EA016262B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение относится к применению препарата в форме раствора для дозирующих ингаляторов под давлением, способных обеспечить доставку терапевтических доз двух или более активных лекарственных веществ в легкое, для изготовления лекарственного средства для предупреждения или лечения тяжелого бронхолегочного заболевания, где все активные лекарственные вещества полностью растворены в препарате, а также два или более активных лекарственных вещества доставляются, по существу, с одинаковым распределением частиц по размерам.
EA200802012A 2006-04-21 2007-04-19 Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением EA016262B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (2)

Publication Number Publication Date
EA200802012A1 true EA200802012A1 (ru) 2009-04-28
EA016262B1 EA016262B1 (ru) 2012-03-30

Family

ID=38230023

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802012A EA016262B1 (ru) 2006-04-21 2007-04-19 Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением

Country Status (21)

Country Link
US (4) US20060257324A1 (ru)
EP (1) EP2010190B1 (ru)
JP (1) JP5289306B2 (ru)
KR (1) KR101311662B1 (ru)
CN (4) CN106074359A (ru)
AU (1) AU2007241336C1 (ru)
BR (1) BRPI0709510A2 (ru)
CA (1) CA2649556C (ru)
CY (1) CY1114215T1 (ru)
DK (1) DK2010190T3 (ru)
EA (1) EA016262B1 (ru)
ES (1) ES2424753T3 (ru)
HR (1) HRP20130835T1 (ru)
ME (1) ME02342B (ru)
MX (1) MX2008013460A (ru)
PL (1) PL2010190T3 (ru)
PT (1) PT2010190E (ru)
RS (1) RS52940B (ru)
SI (1) SI2010190T1 (ru)
WO (1) WO2007121913A2 (ru)
ZA (1) ZA200808965B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CZ301676B6 (cs) * 2001-03-30 2010-05-19 Jagotec Ag Farmaceutický suspenzní aerosolový prípravek pro inhalaci a použití soli karboxylové kyseliny
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
MXPA06013189A (es) * 2004-05-13 2007-02-14 Chiesi Farma Spa Productos medicinales de formulacion en aerosol que tienen estabilidad quimica mejorada.
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
AU2006269961B2 (en) * 2005-07-15 2012-07-19 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2429297A4 (en) * 2009-05-15 2013-12-25 Map Pharmaceuticals Inc METHOD FOR THE ADMINISTRATION OF DOSE-SAVING QUANTITIES OF FORMOTEROL-FUMARATE BUDESONIDE COMBINATION PARTICLES BY INHALATION
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
EP2435023B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
EA021917B1 (ru) * 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия астмы и copd
EP2515856B1 (en) * 2009-12-23 2014-04-02 Chiesi Farmaceutici S.p.A. Aerosol Formulation for COPD
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
GEP20166479B (en) * 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
EP2536412B1 (en) * 2010-02-16 2014-11-12 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable pharmaceutical composition
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
CN102266560A (zh) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 一种用于治疗气喘的药物组合物
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
AU2014228414B2 (en) 2013-03-15 2018-09-13 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
BR112019005133A2 (pt) 2016-09-19 2019-06-04 Mexichem Fluor Sa De Cv composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
MX2019003099A (es) 2016-09-19 2019-06-10 Mexichem Fluor Sa De Cv Composicion farmaceutica.
ES2891579T3 (es) 2016-09-19 2022-01-28 Mexichem Fluor Sa De Cv Composición farmacéutica
EP3515439B1 (en) * 2016-09-19 2021-12-15 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
IL265349B2 (en) * 2016-09-19 2023-03-01 Mexichem Fluor Sa De Cv Pharmaceutical composition
AU2019282562A1 (en) 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
IL293328A (en) 2019-12-02 2022-07-01 Chiesi Farm Spa Stainless steel canister for pressurized metered dose inhalers
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
EP4221707A1 (en) 2020-09-29 2023-08-09 Aerorx Therapeutics LLC Liquid formulations of indacaterol
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0616525T3 (da) 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
PT613371E (pt) * 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
ES2178817T3 (es) * 1997-02-05 2003-01-01 Jago Res Ag Formulaciones medicinales de aerosol.
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338753C (en) * 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
PL209212B1 (pl) 2002-03-01 2011-08-31 Chiesi Farma Spa Superdrobny preparat formoterolu
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
JP4607112B2 (ja) * 2003-08-11 2011-01-05 グラクソ グループ リミテッド 医薬定量噴霧式吸入器及び前記吸引器に関連する方法
WO2005077339A1 (en) * 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ATE404186T1 (de) * 2004-10-12 2008-08-15 Generics Uk Ltd Verfahren zur herstellung von suspensionsaerosolformulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
CA2597716A1 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
US11213485B2 (en) 2022-01-04
PL2010190T3 (pl) 2013-11-29
EP2010190B1 (en) 2013-06-12
JP5289306B2 (ja) 2013-09-11
ES2424753T3 (es) 2013-10-08
CN106074359A (zh) 2016-11-09
KR101311662B1 (ko) 2013-09-25
AU2007241336B2 (en) 2012-12-06
CA2649556C (en) 2014-04-15
MX2008013460A (es) 2008-10-29
CA2649556A1 (en) 2007-11-01
JP2009534333A (ja) 2009-09-24
US10525006B2 (en) 2020-01-07
WO2007121913A3 (en) 2008-03-06
AU2007241336A1 (en) 2007-11-01
CN101389341A (zh) 2009-03-18
CY1114215T1 (el) 2016-08-31
US20090130026A1 (en) 2009-05-21
CN105963249A (zh) 2016-09-28
EP2010190A2 (en) 2009-01-07
DK2010190T3 (da) 2013-08-26
EA016262B1 (ru) 2012-03-30
ME02342B (me) 2016-06-20
US20200085729A1 (en) 2020-03-19
BRPI0709510A2 (pt) 2011-07-19
US20060257324A1 (en) 2006-11-16
US20170065518A1 (en) 2017-03-09
RS52940B (en) 2014-02-28
WO2007121913A2 (en) 2007-11-01
AU2007241336C1 (en) 2023-06-29
SI2010190T1 (sl) 2013-10-30
PT2010190E (pt) 2013-08-26
KR20080110985A (ko) 2008-12-22
ZA200808965B (en) 2009-12-30
HRP20130835T1 (hr) 2013-10-25
CN102908308A (zh) 2013-02-06

Similar Documents

Publication Publication Date Title
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
CY1119805T1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
DE602007010276D1 (de) Trockenpulver-inhaliergerät zur gleichzeitigen verabreichung von mehr als einem medikament
DE602005016410D1 (de) Verbessertes medizinprodukt
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
EA201391689A1 (ru) Система доставки лекарственного средства
SE0402345L (sv) Uppmätt läkemedelsdos
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
MX2013003523A (es) Composicion farmaceutica de dosis baja.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
SE0303091D0 (sv) Combined doses of tiotropium andfluticasone
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
RU2010140888A (ru) Улучшенные противораковые терапии
CN102727515A (zh) 一种治疗脚气的药物制剂
JP2010519274A5 (ru)
EA200801854A1 (ru) Новые композиции
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
RU2021119487A (ru) Комбинированное лекарственное средство, обладающее противовирусным эффектом для профилактики заражения SARS-CoV-2
UA144734U (uk) Спосіб лікування вірусних інфекційних захворювань

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

ND4A Extension of term of a eurasian patent
MF4A Revocation of a eurasian patent as invalid entirely

Designated state(s): RU